Optimi Health Corp.
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.
Small Pharma has completed enrollment in its Phase 2a clinical trial of its intravenous formulation of DMT – candidate SPL026 – with psychotherapy for the treatment...
Revive Therapeutics has announced that it is working on its first Phase I/II clinical study to evaluate oral psilocybin in the treatment of methamphetamine use disorder.
The ‘Microdosing and Meditation Study’ is aiming to observe how meditation skills evolve over three months of regular meditation practice and whether, how, and for whom...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has provided Mindset Pharma with Scientific Advice on a range of points to finalise its MSP-1014 clicnial...
The clinical trial will be testing the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant post-traumatic stress disorder (PTSD).
Revitalist and Wake Network, Inc.
Algernon Pharmaceuticals has received approval to conduct a Phase 1 clinical study of an intravenous formulation (IVF) of DMT for the treatment of stroke in the...
Drug discovery and development company Mindset Pharma has filed for national patents protecting “Family 1” – second-generation psilocybin analogues – in 16 different countries, including South...